GSK plc (NYSE:GSK) Shares Purchased by Range Financial Group LLC

Range Financial Group LLC increased its position in shares of GSK plc (NYSE:GSK) by 11.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,019 shares of the pharmaceutical company’s stock after acquiring an additional 1,117 shares during the period. Range Financial Group LLC’s holdings in GSK were worth $472,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Fisher Asset Management LLC grew its holdings in GSK by 10.8% during the fourth quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock worth $558,330,000 after acquiring an additional 1,465,165 shares during the period. Primecap Management Co. CA grew its holdings in GSK by 0.3% during the fourth quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock worth $448,032,000 after acquiring an additional 30,600 shares during the period. Royal Bank of Canada increased its stake in GSK by 5.1% in the 3rd quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock worth $292,896,000 after purchasing an additional 389,871 shares in the last quarter. Morgan Stanley increased its stake in GSK by 2.1% in the 3rd quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock worth $273,744,000 after purchasing an additional 156,480 shares in the last quarter. Finally, Provident Trust Co. increased its stake in GSK by 53.6% in the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after purchasing an additional 1,297,385 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Up 0.2 %

NYSE:GSK opened at $40.55 on Tuesday. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The stock’s 50-day moving average is $42.56 and its two-hundred day moving average is $41.16. The stock has a market cap of $84.04 billion, a PE ratio of 14.69, a price-to-earnings-growth ratio of 1.22 and a beta of 0.66.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The firm had revenue of $9.34 billion for the quarter, compared to the consensus estimate of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. As a group, equities research analysts forecast that GSK plc will post 4.11 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a $0.3762 dividend. This represents a $1.50 annualized dividend and a yield of 3.71%. This is an increase from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s payout ratio is currently 53.26%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GSK. The Goldman Sachs Group began coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target on the stock. Berenberg Bank raised GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Finally, Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.